Arrhythmias Focused Review. Who Needs An ICD?
|
|
- Maria Sanders
- 6 years ago
- Views:
Transcription
1 Who Needs An ICD? Cesar Alberte, MD, Douglas P. Zipes, MD, Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN Sudden cardiac arrest is one of the most common causes of death in developed countries. It has an incidence of 3 million cases/year worldwide and an overall survival rate 1%. In the US, 450,000 people die suddenly every year, and only 5% are successfully resuscitated. The most common underlying cause is ischemic heart disease, present in about 80% of the cases. The results of recent clinical trials have broadened the indications for implantable cardiodefibrillator (ICD) implantation beyond the cardiac arrest survivor. The purpose of this review is to analyze the different clinical presentations of patients for whom an ICD becomes the primary therapeutic modality and the clinical studies that support its efficacy (Figure 1). Indications for an ICD Secondary Prevention of Sudden Cardiac Death Historical controls from studies in the 1970s and early 1980s suggest that the recurrence rate in survivors of sudden cardiac death (SCD) approximates 15 25% per year. Current medical therapy in high-risk SCD survivors has reduced the rate of SCD to 1 2% per year. Because most of these patients have significant coronary artery disease, they die from heart failure. This shifts the cause of death from arrhythmic to non-arrhythmic, making total mortality a necessary end point of any clinical trial assessing the use of ICD as secondary prevention. Secondary prevention trials. Three landmark clinical trials (Table 1) support the use of ICD therapy in survivors of SCD with ischemic heart disease. The Cardiac Arrest Survival in Hamburg (CASH) randomized 349 cardiac arrest survivors regardless of the underlying disease or ventricular function to ICD, amiodarone, metoprolol or propafenone. After 2 years, there was a significant difference in SCD rate favorable to the ICD, but there was no difference in total mortality between ICD, amiodarone, or metoprolol. Because of increased mortality in the group taking propafenone, this agent was discontinued for the rest of the trial. After a 5-year, there was a 23% reduction in total mortality in patients receiving an ICD compared to those treated with amiodarone and metoprolol. However, when amiodarone and metoprolol were analyzed separately, the significant difference among the three groups was lost. The Antiarrhythmic Drug Vs. Implantable Defibrillator (AVID) trial enrolled 1016 patients with previous ventricular tachycardia (VT), ventricular fibrillation (VF) or arrhythmia-related syncope for randomization of ICD vs. sotalol or amiodarone (most of the drug patients received Arrhythmias Focused Review amiodarone). At 3 years, the ICD provided a 31% relative reduction and a 7% absolute reduction in total mortality. An analysis of mortality based on the left ventricular ejection fraction (LVEF) further clarified the impact of the study. In patients with a LVEF 35%, there was no difference in survival between either group; in patients with LVEF 20 34%, ICD had the greatest benefit; finally, in patients with LVEF 20%, there was a nonstatistically significant mortality reduction in the ICD group. The Canadian Implantable Defibrillator (CIDS) used similar enrollment criteria as AVID (but also included patients with unexplained syncope who had VT induction during electrophysiologic testing) to randomize 659 patients to amiodarone or ICD. After a 5-year, the total mortality was not significantly reduced with the ICD compared to amiodarone, and there was also a nonsignificant reduction in arrhythmic death. With the use of a multivariate risk model and applying age (older than 70 years), LVEF (equal or less than 35%) and NYHA class (III or IV) as independent predictors of risk, there was significant reduction of death from the ICD in patients with two or more risk factors. Individually, and when combined in a meta-analysis, these three trials support the following ICD indications for secondary prevention of SCD: 1. Spontaneous sustained VT or VF not due to a transient or reversible cause (Class I Indication). 2. Syncope of undetermined origin with clinically relevant, hemodynamically sustained VT or VF induced at electrophysiologic study when antiarrhythmic drug therapy is ineffective, not tolerated or not preferred (Class I Indication). Primary Prevention of SCD in Ischemic Heart Disease Because SCD frequently can be the initial clinical presentation of ischemic heart disease, a major effort has been undertaken to identify therapeutic strategies for primary prevention. The Multicenter Automatic Defibrillator Implantation trial (MADIT) was the first study to demonstrate the benefit of an ICD for primary prevention of SCD in a high-risk, asymptomatic population. A total of 196 patients with a prior myocardial infarction, LVEF less than 35%, nonsustained VT and inducible sustained monomorphic VT that was unresponsive to procainamide were randomized to ICD vs. antiarrhythmic therapy (primarily amiodarone). This very high-risk group experienced a 54% reduction in total mortality and a 75% reduction in arrhythmic mortality with ICD therapy. At about the same time, the CABG Patch trial enrolled 900 patients undergoing coronary bypass surgery with LVEF 35% and a positive signal-averaged ECG, to receive concomitant ICD vs medical therapy to 2002 by the American College of Cardiology /02/$22.00 Published by Elsevier Science Inc. PII S (02)00867-X 77
2 Figure 1. Who Needs an ICD? reduce risk of arrhythmic death. No reduction in total mortality was found. Another landmark trial was the Multicenter Unsustained Tachycardia (MUSTT) trial that included 704 patients with coronary artery disease, asymptomatic nonsustained VT, an LVEF 40% and inducible VT in an electrophysiology study. Patients were randomized to no therapy or electrophysiologically guided antiarrhythmic therapy or an ICD if at least one antiarrhythmic agent was ineffective. At 5 years, the treated group had a reduction in total mortality and arrhythmic death of 55 60%, and this was virtually entirely attributed to ICD therapy, with no difference in outcome between patients receiving no therapy and those treated with an antiarrhythmic drug alone. The demonstration in the MADIT and MUSTT trials of a consistent superiority of ICD therapy over drug therapy has made unnecessary the requirement to show failure of a class I antiarrhythmic agent before implanting an ICD. Importantly, a registry of patients from MUSTT with noninducible VT showed a 44% death rate at 5 years. This observation can be related to the results of a recent trial that will broaden the indications for ICD: the MADIT-II trial. In this trial, patients with prior Table 1. ICD Trials for Primary and Secondary SCD Prevention Trial Number of Patients Enrolled Enrollment Criteria Event Rates in the ICD Arm Event Rates in the Non-ICD Arm Conclusion CASH 288 SCD survivors with documented ventricular arrhythmia AVID 1016 SCD survivors; sustained VT with syncope; hemodynamically significant sustained VT with EF 40% CIDS 659 SCD survivors; sustained VT with syncope; hemodynamically significant sustained VT with EF 35%; unmonitored syncope with previously known VT MADIT 196 Prior MI; EF 35%; asymptomatic NSVT; inducible VT on EPS CABG-Patch 1055 Elective CABG; EF 35%; abnormal signal-averaged ECG MUSTT 704 CAD, EF 40%; asymptomatic (161 received ICD) NSVT; inducible VT on EPS 36.4% mortality rate 44.4% mortality rate 23% nonsignificant reduction in all-cause mortality in the ICD group after 5-year 15.8% mortality rate 24% mortality rate 31% significant reduction in all-cause mortality in the ICD group after 3-year 6.7% cardiac death per year 8.6% cardiac death per year 20% nonsignificant reduction in all-cause mortality in the ICD group after 3-year 15 deaths 39 deaths 54% significant reduction in all-cause mortality in the ICD group after 27- month mean 101 deaths 95 deaths No improved survival with ICD 24% mortality rate 55% mortality rate 55% significant reduction in all-cause mortality in the ICD group after 5-year MADIT II 1232 Prior MI, EF 30% 14.2% mortality rate 19.8% mortality rate 31% significant reduction in all-cause mortality in the ICD group after 20- month mean 78
3 myocardial infarction and LVEF 30% were included. No ventricular arrhythmia was required. A total of 1232 patients were randomized to ICD vs. conventional postmyocardial infarction medical therapy. The ICD group had a 31% reduction in total mortality, supporting a potential indication of an ICD for postmyocardial infarction patients with significant reduction of LVEF. Additional future analysis of different clinical subgroups of patients participating in MADIT-II will probably clarify which patients derive the major benefits of an ICD. These trials support ICD indications as primary prevention of SCD in patients with ischemic heart disease who have: 1. Nonsustained VT with coronary disease, prior MI, LVEF 35% and inducible VF or sustained VT at EP study that is not suppressible by a Class I antiarrhythmic drug (Class I Indication). 2. Nonsustained VT with coronary artery disease (CAD), prior MI, LVEF 40% and inducible sustained VT or VF at EP study (Class IIb Indication). 3. Prior MI and LVEF 30%. This indication has not yet been approved but is likely to be in the near future. Primary Prevention of SCD in Nonischemic Dilated Cardiomyopathy The indication of an ICD as prophylactic therapy for SCD in patients with nonischemic dilated cardiomyopathy is still uncertain. Risk stratification of these patients is difficult because there are few clinical predictors specific for SCD. A study currently in progress, the SCD-HeFT trial, compares the mortality benefit of an ICD vs. amiodarone and placebo in this patient population. A smaller trial, the Cardiomyopathy Trial (CAT), was prematurely terminated due to the absence of mortality benefit from ICD vs. medical therapy. The only current indication for ICD implantation in this population is secondary prevention after an episode of resuscitated sudden death or the presence of VT-induced syncope (Class I Indication). Syncope The approach to patients presenting with syncope with a background of ischemic heart disease was discussed earlier. An electrophysiology study to evaluate for the presence of sustained ventricular arrhythmias is indicated. Patients with advanced non-ischemic cardiomyopathy presenting with syncope also have a very high risk of SCD. A very small study done nearly 10 years ago examined patients with idiopathic dilated cardiomyopathy, unexplained syncope and a negative electrophysiology study. This cohort received an ICD and during, 50% of these patients had an appropriate shock by the device over a 2-year period. We believe that patients with unexplained syncope should be referred for electrophysiology study to assess their need for ICD despite the limited data regarding this question. T-wave alternans is a promising non-invasive risk stratifier that may be equivalent to or better than electrophysiology study when applied to high-risk populations. Its value in low-risk patients still needs to be validated in a large population study. Long QT and Brugada Syndrome The decision-making process for secondary prevention of SCD in these two conditions is very simple: an ICD is indicated. A similar approach should be used for the patient with sustained ventricular arrhythmias or recurrent syncope despite medical therapy. Implantation of an ICD in patients with long QT syndrome must not replace additional therapy with beta-blockers. The possible intensification of a sympathetic discharge induced by painful shocks can trigger a storm of torsade de pointes. A more difficult decision is the patient with electrocardiographic manifestation of Brugada or long QT in the absence of symptomatic arrhythmias and/or a family history of SCD. Currently, there is no single or uniform approach to these syndromes, but the threshold to proceed with ICD implantation is decreasing. An individual approach with participation in the final decision by a well-informed patient and family is indicated. Hypertrophic Cardiomyopathy As with long QT and Brugada syndromes, an ICD is indicated as secondary prevention of SCD. For primary prevention, all the screening tests used in other organic heart diseases for potentially lethal ventricular arrhythmias (electrophysiology study, signal-averaged ECG, heart rate variability, continuous ambulatory ECG monitoring, T-wave alternans) have a poor predictive value in hypertrophic cardiomyopathy. Consequently, there is a consensus that the low-risk patient does not need prophylactic therapy. Low risk is defined as an asymptomatic individual with no family history of sudden death, no ventricular arrhythmia, a normal blood pressure response to exercise and a septum 30 mm. The identification of high-risk patients is more problematic, but the presence of two or more of the following risk factors should prompt the decision for ICD placement: family history of sudden death, unexplained syncope, younger than 40 years of age, the presence of abnormal blood response during exercise, severe and diffuse left ventricular hypertrophy (particularly if the maximum wall thickness exceeds 30 mm). There have been attempts to classify patients on the basis of their genetic abnormality, but this approach is not yet fully defined nor is it widely available. Arrhythmogenic Right Ventricular Dysplasia Patients with arrhythmogenic right ventricular dysplasia who present with cardiac arrest, sustained VT, or unequivocal syncope must receive an ICD. For primary prevention, individuals with extensive myocardial disease, frequent episodes of nonsustained ventricular tachycardia, and/or a familial history of unexpected sudden death, should be also 79
4 offered ICD therapy. Finally, any patient with this uncommon diagnosis must be educated regarding his underlying risk and discuss the option of ICD implant as preventive therapy. Contraindications for an ICD The presence of syncope of undetermined etiology in a patient without documented or inducible sustained VT, who does not fit into one of the above categories, is not an indication for an ICD. Patients whose arrhythmias are due to a transient or reversible disorder, such as acute MI, drug ingestion or trauma have been thought not to have a very high risk of recurrence and should not receive an ICD. While recent data from the AVID trial have questioned the validity of that conclusion, the issue is not yet resolved. The presence of incessant VT or VF is a contraindication for ICD therapy. Drug therapy or catheter ablation are therapeutic options, possibly combined with an ICD. Patients with specific arrhythmias that have a definitive cure with catheter or surgical ablation (e.g., VT from right ventricular or left outflow tract, verapamil-sensitive ventricular tachycardia, Wolff-Parkinson-White syndrome, etc.) are generally not ICD candidates because they are thought to be cured by catheter ablation. Individuals with a projected life expectancy 6 months, including drug-refractory heart failure patients who are not candidates for cardiac transplantation, are not candidates for ICD therapy. Impact on Quality of Life by ICD The explanation of the risks and benefits of an ICD is particularly crucial when ICD implantation is offered as primary prevention. The fear of a shock, as well as lifestyle limitations, including driving restrictions in some patients, can outweigh the feeling of security from the ICD. The occurrence of inappropriate discharges for asymptomatic arrhythmias or sinus tachycardia, and the limited life of the device with the need for future procedures, should be discussed. Importantly, in the AVID trial, the quality of life in patients treated with drugs was the same as the ICD patients at 1 year. Summary The ICD, once called a device in search of a disease, has revolutionized the treatment of patients with life-threatening arrhythmias and ranks with the pacemaker as one of the most important therapeutic device advances for patients with life-threatening cardiac arrhythmias. Questions and Answers 1. A 35-year-old man undergoes a routine physical exam as part of a life insurance evaluation. An ECG reveals a pattern that could be consistent with Brugada syndrome. He denies any syncope or family history of sudden death. How would you proceed? A) He should receive an ICD. B) He should undergo an electrophysiology study to assess his risk of sudden death. C) There are not enough data to clearly define the strategy of his evaluation or to indicate ICD implantation at this time. 2. What is the mortality benefit from the use of ICD as secondary prevention therapy according to the AVID trial? A) There is an equal benefit between the use of ICD and antiarrhythmic drugs. B) At 3 years, ICD provided a 31% relative reduction in mortality. C) At 3 years, there was a relative reduction in mortality of 50% in the ICD group. 3. A 62-year-old woman presents to the Emergency Department with an acute myocardial infarction. She is being treated with thrombolytic therapy when she suffers cardiac arrest due to VF. She is appropriately treated and an echocardiogram before discharge indicates a normal LVEF. How would you manage this patient regarding her need for an ICD? A) This is a very high-risk patient for recurrence of SCD. An ICD should be implanted before discharge from the hospital. B) The patient should undergo an electrophysiology study to assess her need of an ICD. C) Her VF arrest was due to the presence of acute ischemia. There is no indication for an ICD. 4. A 22-year-old medical student presents with recurrent episodes of severe lightheadedness associated with palpitations. An echocardiogram ruled out the presence of organic heart disease, but a holter monitor recorded two episodes of sustained monomorphic VT with LBBB-pattern. A) The patient should be referred for electrophysiology study and possible ablation of his ventricular tachycardia. B) ICD is indicated. C) He should be started on amiodarone. If similar episodes recur on this therapy, ICD is the next option. 5. A 16-year-old presents with new onset of palpitations. During his evaluation at the Emergency Department, he is diagnosed with Wolff-Parkinson-White syndrome. He suddenly develops atrial fibrillation, inducing VF. He is resuscitated and referred to you for further management. A) The patient should undergo electrophysiology study for ablation of his accessory pathway. B) Genetic testing to rule out the presence of long QT syndrome is indicated. 80
5 C) An immediate conversation with his parents is necessary to explain his high mortality risk and obtain consent for ICD implantation. The correct answers are 1. C, 2. B, 3. C, 4. A, 5. A. Suggested Reading The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337: Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 1997; 337: Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341: Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101: Gregoratos G, Cheitlin MD, Conill A, et al. ACC/AHA Guidelines for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices: Executive Summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). Circulation 1998;97: Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102: Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335: Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: Address correspondence to Douglas P. Zipes, MD, Krannert Institute of Cardiology, Indiana University School of Medicine, Methodist Hospital, Noyes Pavilion, 1800 North Capitol Ave., Indianapolis, IN
Secondary prevention of sudden cardiac death
Secondary prevention of sudden cardiac death Balbir Singh, MD, DM; Lakshmi N. Kottu, MBBS, Dip Card, PGPCard Department of Cardiology, Medanta Medcity Hospital, Gurgaon, India Abstract All randomised secondary
More informationImplantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
More informationWhat Every Physician Should Know:
What Every Physician Should Know: The Canadian Heart Rhythm Society estimates that, in Canada, sudden cardiac death (SCD) is responsible for about 40,000 deaths annually; more than AIDS, breast cancer
More informationIHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012
IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201203 JANUARY 24, 2012 The IHCP to reimburse implantable cardioverter defibrillators separately from outpatient implantation Effective March 1, 2012, the
More informationICD. Guidelines and Critical Review of Trials. Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011
ICD Guidelines and Critical Review of Trials Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011 Disclosure Relevant Financial Relationship(s) None Off
More informationThe concept of the implantable cardioverter-defibrillator (ICD) was introduced
Review Rohit Kedia, MD Mohammad Saeed, MD, FACC Implantable Cardioverter-Defibrillators Indications and Unresolved Issues Since the implantable cardioverter-defibrillator was first used clinically in 1980,
More informationTachycardia Devices Indications and Basic Trouble Shooting
Tachycardia Devices Indications and Basic Trouble Shooting Peter A. Brady, MD., FRCP Cardiology Review Course London, March 6 th, 2014 2011 MFMER 3134946-1 Tachycardia Devices ICD Indications Primary and
More informationSilvia G Priori MD PhD
The approach to the cardiac arrest survivor Silvia G Priori MD PhD Molecular Cardiology, IRCCS Fondazione Salvatore Maugeri Pavia, Italy AND Leon Charney Division of Cardiology, Cardiovascular Genetics
More informationSynopsis of Management on Ventricular arrhythmias. M. Soni MD Interventional Cardiologist
Synopsis of Management on Ventricular arrhythmias M. Soni MD Interventional Cardiologist No financial disclosure Premature Ventricular Contraction (PVC) Ventricular Bigeminy Ventricular Trigeminy Multifocal
More information20 ng/ml 200 ng/ml 1000 ng/ml chronic kidney disease CKD Brugada 5 Brugada Brugada 1
Symposium 39 45 1 1 2005 2008 108000 59000 55 1 3 0.045 1 1 90 95 5 10 60 30 Brugada 5 Brugada 80 15 Brugada 1 80 20 2 12 X 2 1 1 brain natriuretic peptide BNP 20 ng/ml 200 ng/ml 1000 ng/ml chronic kidney
More informationThe Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia
The Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia By Sandeep Joshi, MD and Jonathan S. Steinberg, MD Arrhythmia Service, Division of Cardiology
More informationThe Italian Implantable Cardioverter- Defibrillator Registry. A survey of the national activity during the years
The Italian Implantable Cardioverter- Defibrillator Registry. A survey of the national activity during the years 2001-2003 Alessandro Proclemer, Marco Ghidina*, Gloria Cicuttini*, Dario Gregori*, Paolo
More informationthat number is extremely high. It s 16 episodes, or in other words, it s 14, one-four, ICD shocks per patient per day.
Doctor Karlsner, Doctor Schumosky, ladies and gentlemen. It s my real pleasure to participate in this session on controversial issues in the management of ventricular tachycardia and I m sure that will
More informationEditorial TREATMENT OF SUDDEN CARDIAC DEATH SURVIVORS: DRUGS VERSUS DEVICE
Editorial TREATMENT OF SUDDEN CARDIAC DEATH SURVIVORS: DRUGS VERSUS DEVICE Patients who survive an episode of sustained ventricular trachycardia (VT) or out-of-hospital ventricular fibrillation (VF) are
More informationManagement of Syncope in Heart Failure. University of Iowa
Management of Syncope in Heart Failure Brian Olshansky University of Iowa 1 Syncope Transient loss of consciousness, with rapid, usually complete, recovery, with or without prodrome A common, non-specific,
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Cardioverter-Defibrillators Page 1 of 32 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Cardioverter-Defibrillators Professional Institutional Original Effective
More informationDo All Patients With An ICD Indication Need A BiV Pacing Device?
Do All Patients With An ICD Indication Need A BiV Pacing Device? Muhammad A. Hammouda, MD Electrophysiology Laboratory Department of Critical Care Medicine Cairo University Etiology and Pathophysiology
More informationSudden death as co-morbidity in patients following vascular intervention
Sudden death as co-morbidity in patients following vascular intervention Impact of ICD therapy Seah Nisam Director, Medical Science, Guidant Corporation Advanced Angioplasty Meeting (BCIS) London, 16 Jan,
More informationJean François Leclercq Department of Rythmology Private Hospital of Parly 2 - Le Chesnay F
SECONDARY PREVENTION of Sudden Death: in which patients? Jean François Leclercq Department of Rythmology Private Hospital of Parly 2 - Le Chesnay F Why an AID is effective? Because it stoppes a VT very
More informationProphylactic ablation
Ventricular tachycardia in ischaemic heart disease. Update on electrical therapy 29 august 2010 Prophylactic ablation Pasquale Notarstefano Cardiovacular Department S. Donato Hospital, Arezzo (IT) Prophylactic
More informationInterQual Care Planning SIM plus Criteria 2014 Clinical Revisions
InterQual Care Planning SIM plus Criteria 2014 Clinical Revisions The Clinical Revisions provide details of changes to InterQual Clinical Criteria. They do not provide information on changes made to CareEnhance
More informationMeta-analysis of the implantable cardioverter defibrillator secondary prevention trials
European Heart Journal (2000) 21, 2071 2078 doi.10.1053/euhj.2000.2476, available online at http://www.idealibrary.com on Meta-analysis of the implantable cardioverter defibrillator secondary prevention
More informationVentricular tachycardia Ventricular fibrillation and ICD
EKG Conference Ventricular tachycardia Ventricular fibrillation and ICD Samsung Medical Center CCU D.I. Hur Ji Won 2006.05.20 Ventricular tachyarrhythmia ventricular tachycardia ventricular fibrillation
More informationSudden cardiac death: Primary and secondary prevention
Sudden cardiac death: Primary and secondary prevention By Kai Chi Chan Penultimate Year Medical Student St George s University of London at UNic Sheba Medical Centre Definition Sudden cardiac arrest (SCA)
More informationAntiarrhythmic Drugs and Ablation in Patients with ICD and Shocks
Antiarrhythmic Drugs and Ablation in Patients with ICD and Shocks Alireza Ghorbani Sharif, MD Interventional Electrophysiologist Tehran Arrhythmia Clinic January 2016 Recurrent ICD shocks are associated
More informationPrimary prevention of SCD with the ICD in Nonischemic Cardiomyopathy
Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: Consulting and Clinical Trials Medtronic
More informationTachycardias II. Štěpán Havránek
Tachycardias II Štěpán Havránek Summary 1) Supraventricular (supraventricular rhythms) Atrial fibrillation and flutter Atrial ectopic tachycardia / extrabeats AV nodal reentrant a AV reentrant tachycardia
More informationThe Multicenter Unsustained Tachycardia Trial (MUSTT)
Effect of Implantable Defibrillators on Arrhythmic Events and Mortality in the Multicenter Unsustained Tachycardia Trial Kerry L. Lee, PhD; Gail Hafley, MS; John D. Fisher, MD; Michael R. Gold, MD; Eric
More informationCRT-P or CRT-D From North Alberta to Nairobi
CRT-P or CRT-D From North Alberta to Nairobi Dr Mzee Ngunga Aga Khan University Hospital Nairobi KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web:
More informationSudden cardiac death accounts for approximately 50%
Annals of Internal Medicine Article Implantable Cardioverter Defibrillators in Primary and Secondary Prevention: A Systematic Review of Randomized, Controlled Trials Justin A. Ezekowitz, MB, BCh; Paul
More informationThe implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease
The implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease Paolo Della Bella, MD Arrhythmia Department and Clinical Electrophysiology
More informationTHE ROLE OF ICD THERAPY FOR PRIMARY PREVENTION Leonard Ganz, M.D. Pittsburgh, PA
THE ROLE OF ICD THERAPY FOR PRIMARY PREVENTION Leonard Ganz, M.D. Pittsburgh, PA Speakers Bureau: Zoll / Lifecore, Sanofi Aventis, Cardionet Consultant: Boston Scientific, St. Jude Medical, Biotronik,
More informationVentricular Tachycardia Ablation. Saverio Iacopino, MD, FACC, FESC
Ventricular Tachycardia Ablation Saverio Iacopino, MD, FACC, FESC ü Ventricular arrhythmias, both symptomatic and asymptomatic, are common, but syncope and SCD are infrequent initial manifestations of
More informationWho does not need a primary preventive ICD?
Who does not need a primary preventive ICD? Hildegard Tanner, Bern Universitätsklinik für Kardiologie Disclosure of potential conflicts of interest Travel grants for educational purposes from: Biosense
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review
More informationRecurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm
Recurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm Guy Amit, MD, MPH Soroka University Medical Center Ben-Gurion University of the Negev Beer-Sheva, Israel Disclosures Consultant:
More informationICD Therapy. Disclaimers
ICD Therapy Rodney Horton, MD Texas Cardiac Arrhythmia Institute Texas Cardiovascular, PA Austin, TX Speaker s Bureau St. Jude Medical Medtronic Boston Scientific Disclaimers Clinical Advisory Panel St.
More informationPrimary prevention ICD recipients: the need for defibrillator back-up after an event-free first battery service-life
Chapter 3 Primary prevention ICD recipients: the need for defibrillator back-up after an event-free first battery service-life Guido H. van Welsenes, MS, Johannes B. van Rees, MD, Joep Thijssen, MD, Serge
More informationSudden Cardiac Death and Asians Disclosures
Sudden Cardiac Death and Asians Disclosures 7 February 2009 Asian Heart and Vascular Symposium None Zian H. Tseng, M.D., M.A.S. Assistant Professor of Medicine Cardiac Electrophysiology Section University
More informationSUDDEN CARDIAC DEATH(SCD): Definition
SUDDEN CARDIAC DEATH EPIDEMIOLOGY, PATHOPHYSIOLOGY, PREVENTION & THERAPY Hasan Garan, M.D. Columbia University Medical Center SUDDEN CARDIAC DEATH(SCD): Definition DEATH DUE TO A CARDIAC CAUSE IN A CLINICALLY
More informationOriginal Policy Date
MP 7.01.32 Implantable Cardioverter Defibrillator (ICD) Medical Policy Section Surgery Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return
More informationJournal of the American College of Cardiology Vol. 37, No. 2, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01133-5 Coronary
More informationHeart Failure and Implantable Cardioverter Defibrillator (ICD) Therapy: Update and Perspective on Current Primary Prevention Trials
Journal of Cardiac Failure Vol. 8 No. 3 2002 Perspectives Heart Failure and Implantable Cardioverter Defibrillator (ICD) Therapy: Update and Perspective on Current Primary Prevention Trials LESLIE A. SAXON,
More informationSUDDEN CARDIAC DEATH(SCD): Definition
SUDDEN CARDIAC DEATH EPIDEMIOLOGY, PATHOPHYSIOLOGY, PREVENTION & THERAPY Hasan Garan, M.D. Columbia University Medical Center SUDDEN CARDIAC DEATH(SCD): Definition DEATH DUE TO A CARDIAC CAUSE IN A CLINICALLY
More informationQRS Duration Does Not Predict Occurrence of Ventricular Tachyarrhythmias in Patients With Implanted Cardioverter-Defibrillators
Journal of the American College of Cardiology Vol. 46, No. 2, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.03.060
More informationRisk Stratification of Sudden Cardiac Death
Risk Stratification of Sudden Cardiac Death Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: None Sudden Cardiac Death A Major Public Health Problem > 1/2 of
More informationCatheter Ablation of Recurrent Ventricular Tachycardia Should Be Done Before Antiarrhythmic Therapy with Amiodarone is Tried CONTRA
Catheter Ablation of Recurrent Ventricular Tachycardia Should Be Done Before Antiarrhythmic Therapy with Amiodarone is Tried CONTRA Erik Wissner, MD, F.A.C.C. Director - Magnetic Navigation Laboratory
More information2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline. Top Ten Messages. Eleftherios M Kallergis, MD, PhD, FESC
2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline Top Ten Messages Eleftherios M Kallergis, MD, PhD, FESC Cadiology Department - Heraklion University Hospital No actual or potential
More informationMichel Mirowski and colleagues ABSTRACT CARDIOLOGY. ICD Update: New Evidence and Emerging Clinical Roles in Primary Prevention of Sudden Cardiac Death
ICD Update: New Evidence and Emerging Clinical Roles in Primary Prevention of Sudden Cardiac Death Ronald D. Berger, MD, PhD, FACC ABSTRACT PURPOSE: To review recent major randomized trials of implantable
More informationSudden Cardiac Death What an electrophysiologist thinks a cardiologist should know
Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know Steven J. Kalbfleisch, M.D. Medical Director Electrophysiology Laboratory Ross Heart Hospital Wexner Medical Center Sudden
More informationPolicy #: 168 Latest Review Date: October 2014
Name of Policy: Cardioverter Defibrillator: Implantable Policy #: 168 Latest Review Date: October 2014 Category: Surgery Policy Grade: A Background/Definitions: As a general rule, benefits are payable
More informationESC Stockholm Arrhythmias & pacing
ESC Stockholm 2010 Take Home Messages for Practitioners Arrhythmias & pacing Prof. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Disclosures Small teaching fees from
More informationWearable Cardioverter-Defibrillators
Wearable Cardioverter-Defibrillators Policy Number: 2.02.15 Last Review: 12/2013 Origination: 10/1988 Next Review: 12/2014 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationArrhythmias (II) Ventricular Arrhythmias. Disclosures
Arrhythmias (II) Ventricular Arrhythmias Amy Leigh Miller, MD, PhD Cardiovascular Electrophysiology, Brigham & Women s Hospital Disclosures None Rhythms and Mortality Implantable loop recorder post-mi
More informationDefibrillation threshold testing should no longer be performed: contra
Defibrillation threshold testing should no longer be performed: contra Andreas Goette St. Vincenz-Hospital Paderborn Dept. of Cardiology and Intensive Care Medicine Germany No conflict of interest to disclose
More informationAutomatic External Defibrillators
Last Review Date: April 21, 2017 Number: MG.MM.DM.10dC3v4 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationRe: National Coverage Analysis (NCA) for Implantable Cardioverter Defibrillators (CAG R4)
December 20, 2017 Ms. Tamara Syrek-Jensen Director, Coverage & Analysis Group Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Re: National Coverage Analysis (NCA) for
More informationVentricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center
Ventricular tachycardia and ischemia Martin Jan Schalij Department of Cardiology Leiden University Medical Center Disclosure: Research grants from: Boston Scientific Medtronic Biotronik Sudden Cardiac
More informationClinical Policy: Holter Monitors Reference Number: CP.MP.113
Clinical Policy: Reference Number: CP.MP.113 Effective Date: 05/18 Last Review Date: 04/18 Coding Implications Revision Log Description Ambulatory electrocardiogram (ECG) monitoring provides a view of
More informationThe pill-in-the-pocket strategy for paroxysmal atrial fibrillation
The pill-in-the-pocket strategy for paroxysmal atrial fibrillation KONSTANTINOS P. LETSAS, MD, FEHRA LABORATORY OF CARDIAC ELECTROPHYSIOLOGY EVANGELISMOS GENERAL HOSPITAL OF ATHENS ARRHYTHMIAS UPDATE,
More informationManagement of Ventricular Arrhythmias A Trial-based Approach
Journal of the American College of Cardiology Vol. 34, No. 3, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00273-9 REVIEW
More informationSudden cardiac death (SCD) is a
Management of malignant ventricular arrhythmias and cardiac arrest Richard I. Fogel, MD; Eric N. Prystowsky, MD Sudden cardiac death continues to be a major health problem in the United States, accounting
More informationAtrial fibrillation (AF) is a disorder seen
This Just In... An Update on Arrhythmia What do recent studies reveal about arrhythmia? In this article, the authors provide an update on atrial fibrillation and ventricular arrhythmia. Beth L. Abramson,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Implantable Cardioverter Defibrillators Page 1 of 44 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Implantable Cardioverter Defibrillators Wearable Cardioverter
More informationACC/AHA Guidelines for Ambulatory Electrocardiography: Executive Summary and Recommendations
(Circulation. 1999;100:886-893.) 1999 American Heart Association, Inc. ACC/AHA Practice Guidelines ACC/AHA Guidelines for Ambulatory Electrocardiography: Executive Summary and Recommendations A Report
More informationSubcutaneous Implantable Cardioverter Defibrillator (ICD) System
Subcutaneous Implantable Cardioverter Defibrillator (ICD) System Policy Number: Original Effective Date: MM.06.025 07/01/2015 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 3/24/201701/01/2019
More informationImplantable Cardioverter Defibrillator (ICD)
Medical Coverage Policy Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 0181 Implantable Cardioverter Defibrillator (ICD) Table of Contents Related Coverage Resources
More informationEditorial: Sudden Death in Heart Failure: An Ounce of Prediction is Worth a Pound of Prevention
Editorial: Sudden Death in Heart Failure: An Ounce of Prediction is Worth a Pound of Prevention Sudden Cardiac Death Ragavendra R. Baliga, MD, MBA Consulting Editors James B. Young, MD Sudden cardiac death
More informationPrevention of sudden cardiac death: With an emphasis on sudden cardiac death from ventricular arrhythmias
Prevention of sudden cardiac death: With an emphasis on sudden cardiac death from ventricular arrhythmias The Toronto ACS Summit Toronto, March 1, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology
More informationChapter 2. Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients
Chapter 2 Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients Guido H. van Welsenes, MS, Johannes B. van Rees, MD, C. Jan Willem Borleffs, MD, PhD, Suzanne
More informationSignal-Averaged Electrocardiography (SAECG)
Medical Policy Manual Medicine, Policy No. 21 Signal-Averaged Electrocardiography (SAECG) Next Review: April 2018 Last Review: April 2017 Effective: May 1, 2017 IMPORTANT REMINDER Medical Policies are
More informationPreventing Sudden Death Current & Future Role of ICD Therapy
Preventing Sudden Death Current & Future Role of ICD Therapy Derek V Exner, MD, MPH, FRCPC, FACC, FAHA, FHRS Professor, Libin Cardiovascular Institute of Alberta Canada Research Chair, Cardiovascular Clinical
More informationDevice Update Implantable Cardioverter Defibrillator (ICD) 박상원
2012 년춘계학술대회 Device Update Implantable Cardioverter Defibrillator (ICD) 박상원 Arrhythmia Center, KUMC www.korea-heartrhythm.com Korea University Medical Center Seoul, Korea The Development of ICD by a team
More informationWhere Does the Wearable Cardioverter Defibrillator (WCD) Fit In?
Where Does the Wearable Cardioverter Defibrillator (WCD) Fit In? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor of Medicine Director,
More informationComparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure
HOT TOPIC Cardiology Journal 2010, Vol. 17, No. 6, pp. 543 548 Copyright 2010 Via Medica ISSN 1897 5593 Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart
More informationNew scientific documents from EHRA Management of patients with defibrillator shocks
New scientific documents from EHRA Management of patients with defibrillator shocks Frieder Braunschweig MD PhD FESC Karolinska University Hospital Stockholm, Sweden Evolution of ICD therapy Worldwide
More informationΕνδείξεισ εμφύτευςησ απινιδωτή ςτην «γκρίζα ζώνη» Γεώργιοσ Ανδρικόπουλοσ, MD, PhD, Αν. Δ/ντήσ Καρδιολογικήσ Κλινικήσ ΓΝΑ «Ερρίκοσ Ντυνάν»
Ενδείξεισ εμφύτευςησ απινιδωτή ςτην «γκρίζα ζώνη» Γεώργιοσ Ανδρικόπουλοσ, MD, PhD, Αν. Δ/ντήσ Καρδιολογικήσ Κλινικήσ ΓΝΑ «Ερρίκοσ Ντυνάν» Major Implantable Cardioverter-Defibrillator Trials for Prevention
More informationTitle: Automatic External Defibrillators Division: Medical Management Department: Utilization Management
Retired Date: Page 1 of 7 1. POLICY DESCRIPTION: Automatic External Defibrillators 2. RESPONSIBLE PARTIES: Medical Management Administration, Utilization Management, Integrated Care Management, Pharmacy,
More informationSudden cardiac death is believed to affect as many as
By Michael R Lauer, MD, PhD clinical contributions Many investigators have grappled with defining sudden death. Clinical Management for Survivors of Sudden Cardiac Death Sudden cardiac death is believed
More informationImplantable Cardioverter Defibrillator. Description
Subject: Implantable Cardioverter Defibrillator Page: 1 of 41 Last Review Status/Date: December 2015 Implantable Cardioverter Defibrillator Description The automatic implantable cardioverter defibrillator
More informationEHRA Accreditation Exam - Sample MCQs Cardiac Pacing and ICDs
EHRA Accreditation Exam - Sample MCQs Cardiac Pacing and ICDs Dear EHRA Member, Dear Colleague, As you know, the EHRA Accreditation Process is becoming increasingly recognised as an important step for
More informationDevice Based Therapy for the Failing Heart: ICD and Cardiac Resynchronization Rx
Device Based Therapy for the Failing Heart: ICD and Cardiac Resynchronization Rx Charles Gottlieb, MD Director of Electrophysiology Abington Memorial Hospital Heart Failure Mortality Mechanism of death
More informationCatheter Ablation for Cardiac Arrhythmias
Catheter Ablation for Cardiac Arrhythmias Policy Number: 2.02.01 Last Review: 5/1/2018 Origination: 05/2015 Next Review: 5/1/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
More informationT-Wave Alternans. Policy # Original Effective Date: 06/05/2002 Current Effective Date: 09/17/2014
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationMedical Policy Manual. Topic: Wearable Cardioverter-Defibrillators as a Bridge to Implantable Cardioverter-Defibrillator Placement
Medical Policy Manual Topic: Wearable Cardioverter-Defibrillators as a Bridge to Implantable Cardioverter-Defibrillator Placement Date of Origin: February 5, 2003 Section: Durable Medical Equipment Last
More informationOriginal Article Risk of Death and Recurrent Ventricular Arrhythmias in Survivors of Cardiac Arrest Concurrent With Acute Myocardial Infarction
www.ipej.org 5 Original Article Risk of Death and Recurrent Ventricular Arrhythmias in Survivors of Cardiac Arrest Concurrent With Acute Myocardial Infarction Ish Singla MD*, Haitham Hreybe MD*, Samir
More informationImproving Patient Outcomes with a Syncope Center. Suneet Mittal, MD
Improving Patient Outcomes with a Syncope Center Suneet Mittal, MD Improving Patient Outcomes with a Syncope Center: Early Risk Stratification of Patients who Require Device Therapy Suneet Mittal, MD Director,
More informationChapter 3. Eur Heart J 2009; 30:
Recurrence of Ventricular Arrhythmias in Ischemic Secondary Prevention ICD Recipients: Long-term Followup of the Leiden Out-of- Hospital Cardiac Arrest Study (LOHCAT) C. Jan Willem Borleffs, MD 1, Lieselot
More informationDos and Don t in Cardiac Arrhythmia. Case 1 -ECG. Case 1. Management. Emergency Admissions. Reduction of TE risk -CHADS 2 score. Hospital Admissions
Emergency Admissions Dos and Don t in Cardiac Arrhythmia Tom Wong, MD, FESC Consultant Cardiologist, Honorary Senior Lecturer Royal Brompton & Harefield Hospitals National Heart and Lung Institute, Imperial
More informationMEDICAL POLICY Cardioverter Defibrillators
POLICY........ PG-0224 EFFECTIVE......06/01/09 LAST REVIEW... 01/27/17 MEDICAL POLICY Cardioverter Defibrillators GUIDELINES This policy does not certify benefits or authorization of benefits, which is
More informationSudden Cardiac Death
Sudden Cardiac Death management challenges of a global problem Zayd A. Eldadah, MD, PhD Co-Director, Cardiac Electrophysiology, Washington Hospital Center Director, Cardiac Electrophysiology, Georgetown
More informationWearable Cardioverter-Defibrillators
Wearable Cardioverter-Defibrillators Policy Number: 2.02.15 Last Review: 12/2017 Origination: 10/1988 Next Review: 12/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationSUDDEN CARDIAC DEATH - A PREDICTABLE, AVOIDABLE AND TREATABLE EVENT? *
Proc. R. Coll. Physicians Edinb. 1998; 29:350-356 SUDDEN CARDIAC DEATH - A PREDICTABLE, AVOIDABLE AND TREATABLE EVENT? * Jennifer Adgey, P.W. Johnston and T.P. Mathew, Regional Medical Cardiology Centre,
More informationSeveral studies of the primary prevention. Original Research
Original Research Hellenic J Cardiol 2015; 56: 230-236 Inducibility of Ventricular Arrhythmia and Tachyarrhythmia Recurrences in Patients with Implantable Defibrillator Giuseppe Stabile 1, Paolo Gallo
More informationNoninvasive Predictors of Sudden Cardiac Death
2011 년순환기관련학회춘계통합학술대회 Noninvasive Predictors of Sudden Cardiac Death 영남대학교의과대학순환기내과학교실신동구 Diseases associated with SCD Previous SCD event Prior episode of ventricular tachyarrhythmia Previous myocardial
More informationAsymptomatic WPW Syndrome; Observation or Ablation? 전남대학교병원순환기내과 박형욱
Asymptomatic WPW Syndrome; Observation or Ablation? 전남대학교병원순환기내과 박형욱 Let It Be? Vs. Just Do It? Natural history of asymptomatic WPW Incidence of sudden cardiac death in natural history studies involving
More informationSEMINAIRES IRIS. Sudden cardiac death in the adult. Gian Battista Chierchia. Heart Rhythm Management Center, UZ Brussel. 20% 25% Cancers !
Sudden cardiac death in the adult Gian Battista Chierchia. Heart Rhythm Management Center, UZ Brussel.! " # $ % Cancers National Vital Statistics Report, Vol 49 (11), Oct. 12, 2001. 20% 25% State-specific
More informationICD THERAPIES: are they harmful or just high risk markers?
ICD THERAPIES: are they harmful or just high risk markers? Konstantinos P. Letsas, MD, PhD, FESC LAB OF CARDIAC ELECTROPHYSIOLOGY EVANGELISMOS GENERAL HOSPITAL ATHENS ICD therapies are common In a meta-analysis
More informationThe patient with electric storm
The complex patient in the cardiac care unit: The patient with electric storm Helmut U. Klein University of Rochester Medical Center Heart Research Follow-up Program and Isar Heart Center Muenchen Presenter
More informationRhythm Control: Is There a Role for the PCP? Blake Norris, MD, FACC BHHI Primary Care Symposium February 28, 2014
Rhythm Control: Is There a Role for the PCP? Blake Norris, MD, FACC BHHI Primary Care Symposium February 28, 2014 Financial disclosures Consultant Medtronic 3 reasons to evaluate and treat arrhythmias
More information